Medline Inc. (MDLN)
| Market Cap | 52.80B |
| Revenue (ttm) | 29.14B +12.1% |
| Net Income | 966.00M -21.4% |
| EPS | 1.14 |
| Shares Out | 1.31B |
| PE Ratio | 35.15 |
| Forward PE | 26.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,193,509 |
| Open | 41.81 |
| Previous Close | 41.86 |
| Day's Range | 40.12 - 42.22 |
| 52-Week Range | 34.89 - 50.88 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 50.48 (+25.6%) |
| Earnings Date | May 6, 2026 |
About MDLN
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam g... [Read more]
Financial Performance
In 2025, Medline's revenue was $28.43 billion, an increase of 11.47% compared to the previous year's $25.51 billion. Earnings were $1.16 billion, a decrease of -3.42%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for MDLN stock is "Strong Buy." The 12-month stock price target is $50.48, which is an increase of 25.60% from the latest price.
News
Medline price target lowered to $42 from $48 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Medline (MDLN) to $42 from $48 and keeps a Hold rating on the shares.
Medline price target lowered to $54 from $56 at Bernstein
Bernstein lowered the firm’s price target on Medline (MDLN) to $54 from $56 and keeps an Outperform rating on the shares following quarterly results. The firm notes that companies are
Medline price target lowered to $55 from $60 at Citi
Citi analyst Patrick Donnelly lowered the firm’s price target on Medline (MDLN) to $55 from $60 and keeps a Buy rating on the shares. The firm reduced estimates post the
Medline reports Q1 adjusted EPS 33c, consensus 29c
Reports Q1 revenue $7.35B, consensus $7.16B. “We started 2026 with strong momentum-growing with our existing customers, executing implementations at scale and winning new customers,” said Jim Boyle, c...
Medline backs FY26 adjusted EBITDA view $3.5B-$3.6B
Raises FY26 organic sales view to 8.5%-9.5% from 8%-9%.
Medline issued recall of all neuro sponge products, FDA says
The FDA said in a letter to healthcare providers that on March 13, Medline (MDLN) issued a customer letter stating higher than expected endotoxin levels have been identified on Medline
Medline Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% sales growth, driven by strong Supply Chain Solutions and new customer signings, but adjusted EBITDA declined 11% due to higher costs and tariffs. Full-year organic sales guidance was raised, while EBITDA guidance was maintained, reflecting confidence in mitigation strategies.
Medline Reports First Quarter 2026 Results
Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance r...
Medline share weakness overdone, ‘misinterpretation’-driven, says Leerink
The decline in Medline (MDLN) shares appears overdone and likely driven by a misinterpretation of an FDA-related headline, as the affected products are tied to a third-party supplier and have
FDA revokes approval for several Medline products
The FDA has revoked approval for several Medline (MDLN) products, the agency said on its website.
Medline announces AI robotics partnership with Symbotic
Medline (MDLN) announced a strategic agreement to implement next-generation warehouse automation from Symbotic, an AI-enabled robotics technology company, as part of the company’s ongoing efforts to s...
Medline announces first-in-healthcare AI robotics partnership with Symbotic
Continued investment in next-gen supply chain technology powers Medline's distribution capabilities NORTHFIELD, Ill., April 16, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN) announced a strategic agreem...
US FDA warns Medline over defective heart procedure syringes
The U.S. Food and Drug Administration has warned medical device maker Medline that its syringes used in heart procedures are defective and that the company has failed to fix the problem adequately.
Medline to report first quarter 2026 results on May 6, 2026
NORTHFIELD, Ill., April 08, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report first quarter 2026 financial results on Wednesday, May 6, 2026.
Medline launches custom product fulfillment technology called Pick Pack Pro™
Investment in combined robotic, conveyor and packing technology supports the delivery of medical supplies directly to homes of health plan members NORTHFIELD, Ill., April 6, 2026 /PRNewswire/ -- Medl...
Medline recognizes manufacturing facilities with Golden Cone Safety Award
NORTHFIELD, Ill., April 3, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN), the largest provider of medical-surgical products and supply chain solutions serving all points of care, announced this week its...
Medline receives HIRC Member Choice Awards for supply chain achievement and renews Transparency Badge distinction
Awards selection is highest recognition for healthcare supply chain partnership NORTHFIELD, Ill., April 1, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN), the largest provider of medical-surgical product...
Medline's growth continues as it breaks ground on 1.2 million sq. ft distribution center in Midlothian, Texas
Groundbreaking is first operational initiative as a publicly traded company on its continued trajectory of growth NORTHFIELD, Ill., March 11, 2026 /PRNewswire/ -- Medline [Nasdaq: MDLN] announced duri...
Medline Transcript: Barclays 28th Annual Global Healthcare Conference
Strong Q4 and FY2025 results were driven by robust new customer signings, high fill rates, and technology investments. 2026 guidance projects 8%-9% organic growth and $3.5-$3.6 billion EBITDA, with tariff headwinds expected to normalize by year-end. Expansion in labs, dental, and international markets continues.
Medline resumed with a Buy at Citi
Citi resumed coverage of Medline (MDLN) with a Buy rating and $60 price target following a period of suspension. The company’s Q4 report came in well ahead of expectations on
Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters' option to purchase additional shares
NORTHFIELD, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its secondary offering of 86,250,000 shares of Medline Inc.'s Class A co...
Medline price target raised to $53 from $50 at JPMorgan
JPMorgan raised the firm’s price target on Medline (MDLN) to $53 from $50 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first on
Medline Awards Distribution Center of the Year and SAFE Awards
NORTHFIELD, Ill., March 9, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN), the largest provider of medical-surgical products and supply chain solutions serving all points of care, announced this week its...
Medline price target raised to $60 from $55 at Tigress Financial
Tigress Financial analyst Ivan Feinseth raised the firm’s price target on Medline (MDLN) to $60 from $55 and keeps a Buy rating on the shares. Multiple durable growth levers support
Medline 75M share Secondary priced at $41.00
The deal priced below last closing price of $42.88. Goldman Sachs, Morgan Stanley, BofA and JPMorgan are acting as joint book running managers for the offering.